Is Cdc25 a druggable target?

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Anti-Cancer Agents in Medicinal Chemistry

• Publication date

  2008-11-30

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/187152008786847738PMID 19075566PMCID PMC2752834
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Receptor-Based Virtual Ligand Screening for the Identification of Novel CDC25 Phosphatase Inhibitors

  2008cited by this paper
• NanoLC-MS/MS analysis provides new insights into the phosphorylation pattern of Cdc25B in vivo: full overlap with sites of phosphorylation by Chk1 and Cdk1/cycB kinases in vitro.

  2008cited by this paper
• Induction of Cdc25B regulates cell cycle resumption after genotoxic stress.

  2007cited by this paper
• Strategies for developing protein tyrosine phosphatase inhibitors.

  2007cited by this paper
• Inhibiting transient protein–protein interactions: lessons from the Cdc25 protein tyrosine phosphatases

  2007cited by this paper
• PTP1B as a drug target: recent developments in PTP1B inhibitor discovery.

  2007cited by this paper
• Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide.

  2007cited by this paper
• What's new on CDC25 phosphatase inhibitors.

  2007cited by this paper
• Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability.

  2007cited by this paper
• Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284).

  2007cited by this paper
• Fluorinated NSC as a Cdc25 inhibitor.

  2007cited by this paper
• p53 downregulates expression of the G1/S cell cycle phosphatase Cdc25A

  2007cited by this paper
• Hypoxic Suppression of the Cell Cycle Gene CDC25A in Tumor Cells

  2007cited by this paper
• Nitrogen-containing heterocyclic quinones: a class of potential selective antitumor agents.

  2007cited by this paper
• Cdc25 phosphatases: structure, specificity, and mechanism.

  2007cited by this paper
• CDC25 phosphatases in cancer cells: key players? Good targets?

  2007cited by this paper
• Evaluation of HIF-1 inhibitors as anticancer agents.

  2007cited by this paper
• Targeting protein tyrosine phosphatase to enhance insulin action for the potential treatment of diabetes.

  2007cited by this paper
• Modeling of Cdc25B Dual Specifity Protein Phosphatase Inhibitors: Docking of Ligands and Enzymatic Inhibition Mechanism

  2006cited by this paper
• PM-20, a novel inhibitor of Cdc25A, induces extracellular signal–regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo

  2006cited by this paper
• Targeting the PTPome in human disease

  2006cited by this paper
• Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases

  2005cited by this paper
• Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance

  2005cited by this paper
• Inhibitors of protein tyrosine phosphatases: next-generation drugs?

  2005cited by this paper
• Redox redux: revisiting PTPs and the control of cell signaling.

  2005cited by this paper
• Sesterterpenoids and an alkaloid from a Thorectandra sp. as inhibitors of the phosphatase Cdc25B.

  2005cited by this paper
• Redox Regulation of Cdc25B by Cell-Active Quinolinediones

  2005cited by this paper
• A novel cinnamic acid derivative that inhibits Cdc25 dual‐specificity phosphatase activity

  2005cited by this paper
• NAD(P)H:Quinone Oxidoreductase-1-Dependent and -Independent Cytotoxicity of Potent Quinone Cdc25 Phosphatase Inhibitors

  2004cited by this paper
• Toward a pharmacophore for kinase frequent hitters.

  2004cited by this paper
• Protein tyrosine phosphatases in the human genome.

  2004cited by this paper
• A novel synthetic inhibitor of CDC25 phosphatases: BN82002.

  2004cited by this paper
• Design and synthesis of macrocyclic inhibitors of phosphatase cdc25B.

  2004cited by this paper
• Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones.

  2003cited by this paper
• Low molecular weight inhibitors of Myc–Max interaction and function

  2003cited by this paper
• Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer

  2003cited by this paper
• Regulation of Cdc25A Half-life in Interphase by Cyclin-dependent Kinase 2 Activity*

  2003cited by this paper
• Dual-specificity phosphatases as targets for antineoplastic agents

  2002cited by this paper
• Syntheses and biological activities of a novel group of steroidal derived inhibitors for human Cdc25A protein phosphatase.

  2001cited by this paper
• Cdc25B Functions as a Novel Coactivator for the Steroid Receptors

  2001cited by this paper
• The Cell Cycle-Regulatory CDC25A Phosphatase Inhibits Apoptosis Signal-Regulating Kinase 1

  2001cited by this paper
• Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25.

  2001cited by this paper
• Role of quinones in toxicology.

  2000cited by this paper
• The solid phase synthesis of tetrahydroisoquinolines having cdc25B inhibitory activity.

  2000cited by this paper
• Pharmacological rescue of mutant p53 conformation and function.

  1999cited by this paper
• Generation of an Ugi library of phosphate mimic-containing compounds and identification of novel dual specific phosphatase inhibitors.

  1999cited by this paper
• Dysidiolide and related gamma-hydroxy butenolide compounds as inhibitors of the protein tyrosine phosphatase, CDC25.

  1999cited by this paper
• A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation.

  1997cited by this paper
• CDC25 phosphatases as potential human oncogenes.

  1995cited by this paper
• Dnacin A1 and dnacin B1 are antitumor antibiotics that inhibit cdc25B phosphatase activity.

  1994cited by this paper
• Purification of the major protein-tyrosine-phosphatases of human placenta.

  1988cited by this paper

• A novel dual CDC25-HDAC inhibitor suppresses glioblastoma progression via chromosomal passenger complex disruption.

  2025cites this paper
• Purified anacardic acids exert multiple neuroprotective effects in pesticide model of Parkinson's disease: in vivo and in silico analysis

  2020cites this paper
• Pharmacophore-guided discovery of CDC25 inhibitors causing cell cycle arrest and tumor regression

  2019cites this paper
• Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines

  2018cites this paper
• Pharmacophore-guided discovery of CDC25 inhibitors causing cell cycle arrest and cell death

  2018cites this paper
• Small molecule targeting of PTPs in cancer.

  2017cites this paper
• New Approaches to Difficult Drug Targets: The Phosphatase Story

  2017cites this paper
• Phosphatases and solid tumors: focus on glioblastoma initiation, progression and recurrences.

  2017cites this paper
• Conformational flexibility of the complete catalytic domain of Cdc25B phosphatases

  2016cites this paper
• Cdc25 Family Phosphatases in Cancer

  2016cites this paper
• UNIVERSITA ’ DEGLI STUDI DI NAPOLI “ FEDERICO II ” DIPARTIMENTO DI FARMACIA DOTTORATO DI RICERCA IN SCIENZA DEL FARMACO XXVIII CICLO IDENTIFICATION OF NOVEL INHIBITORS OF CDC 25 PHOSPHATASES AS NEW ANTI-MELANOMA AGENTS BY LIGAND-AND STRUCTURE-BASED VIRTUAL SCREENING STUDIES

  2016cites this paper
• Characterization of the Cytotoxic Activity ODE-adefovir in AML

  2015cites this paper
• Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B.

  2015cites this paper
• Is RK-682 a promiscuous enzyme inhibitor? Synthesis and in vitro evaluation of protein tyrosine phosphatase inhibition of racemic RK-682 and analogues.

  2015cites this paper
• Investigational inhibitors of PTP4A3 phosphatase as antineoplastic agents

  2014cites this paper
• Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer

  2014cites this paper
• Multicellular tumor spheroid models to explore cell cycle checkpoints in 3D

  2013cites this paper
• HUMAN POLYOMAVIRUS BK AND MOLECULAR ACTORS IN PROSTATE CANCER DEVELOPMENT: RESULTS, QUESTIONS, PERSPECTIVES OF A FOUR YEAR LONG STUDY

  2012cites this paper
• The role of Cdc25A in the regulation of cell proliferation and apoptosis.

  2012cites this paper
• Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.

  2012cites this paper
• GeneFriends: An online co-expression analysis tool to identify novel gene targets for aging and complex diseases

  2012cites this paper
• CDC25 phosphatase inhibitors: an update.

  2012cites this paper
• G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2).

  2010cites this paper
• Targeting protein tyrosine phosphatases for anticancer drug discovery.

  2010cites this paper
• Flexibility and inhibitor binding in cdc25 phosphatases

  2010cites this paper
• CDC25A mRNA levels significantly correlate with Ki-67 expression in human glioma samples

  2010cites this paper
• A Novel Mechanism of Indole-3-Carbinol Effects on Breast Carcinogenesis Involves Induction of Cdc25A Degradation

  2010cites this paper
• A Probable Target for Novel Anticancer Agents: Cdc25 Phosphatases as Cyclin-Dependent Kinase Inhibitors

  2010cites this paper
• A case study from the chemistry core of the Pittsburgh Molecular Library Screening Center: the Polo-like kinase polo-box domain (Plk1-PBD).

  2009cites this paper
• CDC25A and B dual-specificity phosphatase inhibitors: potential agents for cancer therapy.

  2009cites this paper
• Phosphatases as targets for cancer treatment.

  2009cites this paper
• Structure-based virtual screening approach to identify novel classes of Cdc25B phosphatase inhibitors.

  2009cites this paper